$Lipocine (LPCN.US)$ NEWS LIPOCINE ANNOUNCES LATE BREAKING O...
NEWS
LIPOCINE ANNOUNCES LATE BREAKING ORAL PRESENTATION OF DATA FROM THE PHASE 2 STUDY OF LPCN 1148 AT EASL CONGRESS 2024
Lipocine Inc. announced that data from the Phase 2 study of LPCN 1148 will be presented at the EASL Congress 2024 in Italy. The study shows improvement in sarcopenia and hepatic encephalopathy in cirrhosis patients.
Positive
Data from the Phase 2 study of LPCN 1148 selected for late breaking oral presentation at EASL Congress 2024.
Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in patients with cirrhosis.
Positive
Data from the Phase 2 study of LPCN 1148 selected for late breaking oral presentation at EASL Congress 2024.
Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in patients with cirrhosis.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
9543
Followers
55
Following
116K
Visitors
Follow